A Study of SPY002-091 in Healthy Volunteers

Description

This is a Phase 1, randomized, double-blind, placebo-controlled, single- dose, first in human safety, tolerability, and pharmacokinetic study of SPY002-091 in healthy participants.

Conditions

Healthy

Talk to us

Study Overview

On this page

Study Details

Study overview

This is a Phase 1, randomized, double-blind, placebo-controlled, single- dose, first in human safety, tolerability, and pharmacokinetic study of SPY002-091 in healthy participants.

A Phase 1, Randomized, Double-Blind, Placebo-Controlled, Single Ascending Dose Study of the Safety, Tolerability, and Pharmacokinetics of SPY002-091 in Healthy Participants

A Study of SPY002-091 in Healthy Volunteers

Condition
Healthy
Intervention / Treatment

-

Contacts and Locations

Cypress

Spyre Site 1, Cypress, California, United States, 90630

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

For general information about clinical research, read Learn About Studies.

Eligibility Criteria

  • * Healthy men and women
  • * Willing and able to attend the necessary visits to the CRU, comply with all testing requirements, remain at the study site unit for the duration of the confinement period and return for the outpatient visits
  • * Participation in more than one cohort
  • * Evidence of clinically significant abnormality or disease
  • * Known history of illicit drug use or drug abuse, harmful alcohol use or alcoholism, and/or smoking or nicotine-containing product use within 3 months prior to the first dose of study drug
  • * History of severe allergic reactions or hypersensitivity
  • * Donation or loss of \>1 unit of whole blood within 1 month prior to dosing

Ages Eligible for Study

18 Years to 65 Years

Sexes Eligible for Study

ALL

Accepts Healthy Volunteers

Yes

Collaborators and Investigators

Spyre Therapeutics, Inc.,

Joshua Friedman, MD, STUDY_CHAIR, Spyre Therapeutics

Study Record Dates

2026-06-22